Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Gradalis Inc. Stories

2013-08-20 08:29:39

Growth and commercialization at the forefront for bio-therapeutics company DALLAS, Aug. 20, 2013 /PRNewswire/ -- Gradalis, Inc. today announced the appointment of Phillip B. Maples, Ph.D., as executive vice president and chief technical officer. Maples joined Gradalis in 2005 as its first employee and has more than 28 years of international healthcare and biotechnology experience. Maples will continue to oversee product development, manufacturing and quality assurance for the...

2013-07-23 08:30:35

Former Prometheus Laboratories CEO sees opportunity for growth at innovative biotech Gradalis DALLAS, July 23, 2013 /PRNewswire/ -- Gradalis, Inc. today announced the appointment of Joseph M. Limber as president and chief executive officer. Limber, a pharmaceutical veteran, brings more than 30 years of life sciences management experience to the position. In this role, Limber will utilize his vast pharmaceutical business acumen and commercial expertise as the company focuses on...

2013-05-15 12:33:21

Interim Phase II Data and Follow-Up Analysis of Phase I Data Presented at Annual Meeting of the American Society of Gene and Cell Therapy DALLAS, May 15, 2013 /PRNewswire/ -- Today Gradalis, Inc. announced that FANG(TM), the company's tumor-based personalized cancer vaccine, elicits an immune response and delays time to recurrence in advanced stage ovarian cancer patients by more than one year compared to patients who received standard of care. Interim analysis of the Phase II...

2013-01-03 08:25:50

DALLAS, Jan. 3, 2013 /PRNewswire/ -- Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG(TM), through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG. In addition, the funding will be used to progress the clinical and preclinical development of the company's bifunctional shRNA platform. "The boost that...

2012-07-11 02:25:39

DALLAS, July 11, 2012 /PRNewswire/ -- Today Baylor College of Medicine (BCM) and Gradalis, Inc. announced the signing of a Master Collaboration Agreement focused on BCM scientists' use of Gradalis' proprietary bifunctional shRNA (bi-shRNA) platform in BCM's research directed at various biological targets for therapeutic intervention. The translational medicine collaboration covers multiple BCM investigators and multiple therapeutic targets in cancer. This collaboration will further BCM's...

2012-03-01 07:00:00

DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG(TM), the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer compared to...